ASCO 2025 colorectal cancer updates: BREAKWATER & ATOMIC
Автор: VJOncology
Загружено: 2025-07-28
Просмотров: 343
Описание:
Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, gives an overview of the results of the BREAKWATER trial (NCT04607421), which demonstrates a promising response rate and median survival in patients with BRAF V600E-mutant metastatic colorectal cancer being treated with first-line encorafenib plus cetuximab and chemotherapy in BRAF V600E-mutant metastatic colorectal cancer. The trial's results highlight the importance of using the best treatment at any given time. Prof. Lenz also comments the potential for liquid biopsies to guide treatment and the ATOMIC trial (NCT02912559), which may show that an adjuvant treatment with FOLFOX and an immune checkpoint inhibitor is more successful than FOLFOX alone in MSI-high tumors. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
